絞り込み

16424

広告

「vonoprazan」の検索結果

114件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Update on use of vonoprazan: a competitive acid blocker (P-CAB).

Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

Eosinophilic esophagitis in Japan - Focus on response to acid suppressive therapy.

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.

Risk Factors for Delayed Ulcer Healing after Endoscopic Submucosal Dissection of Gastric Neoplasms.

Immune thrombocytopenia induced by vonoprazan fumarate: a single center retrospective study.

Parietal Cell Protrusions and Dilated Oxyntic Glands from Use of Vonoprazan.

Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin.

Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility.

Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.

Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.

Development of a stability- indicating HPLC method for simultaneous determination of ten related substances in vonoprazan fumarate drug substance.

Changes in gefitinib, erlotinib, and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats.

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.

Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.

Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
Sort by
※並べ替えは表示に時間がかかります